Karine Suissa

Obesity Pharmacoepidemiologist. Bridging NutritionalEpi and PharmacoEpi @LDI @JGH (all comments and views posted are my own)

[EASO @EASOobesity]

Semaglutide found effective for severe obesity even in young people who have been treatment resistant for many years, finds randomised controlled trial.

Read more: https://t.co/Ys6zx5sART

#ECO2026

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

Obesity treatment is expected to shift gradually from a one-size-fits-all approach towards more personalised medicine, in which the obesity phenotype and presence of related conditions will determine the treatment strategy https://t.co/IFPyEU8bKn
#obesity

[Novo Nordisk @novonordisk]

#PRESS Our GLP-1 pill for the treatment of obesity and injectable semaglutide 7.2 mg is approved in the EU as we expand global access to obesity care. Read more here: https://t.co/Dbaray0JND

[Karine Suissa @Kaysuiss]

“We’ve seen a lot of these TriNetX studies, and they all seem to have very similar flaws” says Samy Suissa, a pharmacoepidemiologist at McGill University. “[…] always find these spectacular effects, remarkable benefits for drugs on all kinds of outcomes.” https://t.co/gQ01tFo91F

[Daniel J Drucker @DanielJDrucker]

Adiposity and #cancer Will use of GLP-1 medicines bend the curve? Is weight loss the potential mechanistic driver? https://t.co/y8gGtPgdyq

[Michael Weintraub, MD @MWeintraubMD]

Retatrutide in adults with obesity over 104 weeks in the highest dose group had 30.3% weight loss.

Nearly 2/3 reached BMI < 30

1 in 3 reached BMI < 25

[Updates in Medicine @medic_updates]

Pharmacological management of Obesity

[Ming "Tommy" Tang @tangming2005]

Data visualization is a critical step in data analysis. 8 links to bookmark for better data visualization:🧵

[Scott Isaacs @scottisaacsmd]

Insightful commentary in @Nature about rapid weight loss with GLP-1 meds which can lead to significant muscle loss or even #sarcopenia. Muscle-preserving strategies, exercise, adequate protein (~1.2-1.6 g/kg/d), creatine, and promising new agents like #bimagrumab and myostatin inhibitors.
https://t.co/H2LdE79jio

[Scott Isaacs @scottisaacsmd]

Obesity is a disease.
https://t.co/9i0y3sUhPO

[Karine Suissa @Kaysuiss]

🤦‍♀️ completely absurd

[Michael Albert, MD @MichaelAlbertMD]

OptumRx's Zepbound PA requirement is absurd. Must try and fail Orlistat?!!! Someone called and wants their early 2000s obesity medicine back.

Is Lilly not giving you a big enough rebate?

[OAC @ObesityAction]

Leading obesity expert organizations released a statement on the recent SELECT study showing Semaglutide can help prevent heart problems like cardiovascular deaths, strokes and heart attacks in people with obesity.

Learn more: https://t.co/Ur1ZcqrC6s

[Scott Isaacs @scottisaacsmd]

When treating millions of people with GLP-1 medications like #semaglutide and #tirzepatide even relatively rare side effects will occur in a large number of people.
https://t.co/y2QzGuFPeo

[Scott Isaacs @scottisaacsmd]

This article discusses the cardiovascular benefits of new weight loss therapies.
https://t.co/JEqgATWdgf

[ASMBS @ASMBS]

GLP-1s After Bariatric Surgery? How and When https://t.co/lYVjAK2d6c via @medscape

[Neil Floch MD @NeilFlochMD]

American Medical Association calls for insurers to cover weight loss drugs | The Hill #obesity GLP-1 #semaglutide #ZepBound #tirzepatide #Mounjaro https://t.co/Kfi01cc1nf

[Michael Weintraub, MD @MWeintraubMD]

We are halfway up the mountain of clinical trial data to be produced for #tirzepatide.

So far it has demonstrated the greatest efficacy at treating #type2diabetes and #obesity outside of bariatric surgery

https://t.co/Jy66qY2PQf

[Beverly G. Tchang, MD @BevTchangMD]

The notion that #lifestyle should precede medical management of #obesity is not just public opinion.
Unfortunately it is written into the @ObesitySociety guidelines…which are 10 years old and desperately need an update

The truth is that all obesity pharmacotherapy trials are done on the backbone of lifestyle *counseling* (adherence not measured or reported) so many MDs still abide by the “lifestyle first” rule

👉But this is an area of needed #research
👉We need data on “real world” use where counseling may be minimal or nonexistent

Having worked with thousands of patients, I can say some people who are “just” taking the medication without any lifestyle changes are still healthier than before and #HellthInsurance requiring them to prove lifestyle trial before continuing coverage is unethical and harmful

[Karine Suissa @Kaysuiss]

Almost half of the US population is eligible to receive these weight loss drugs, but how many actually have access to them at 12,000$ per year?

[Beverly G. Tchang, MD @BevTchangMD]

AMA urges coverage of #obesity treatments as payers balk at costs https://t.co/ybDl37DWwt via @statnews @elaineywchen

[David Arterburn, MD, MPH @davearterburn]

What to Know About Wegovy’s Rare but Serious Adverse Effects https://t.co/mPbiwZ2WnE